« Return to News | Clinical Intelligence

Amgen's Prolia shows positive results

Tuesday, March 29, 2011 12:58 PM

Amgen has presented new long-term data showing that women with osteoporosis who have been treated with Prolia for up to five years experienced statistically significant, year-to-year increases in lumbar spine and total hip bone mineral density.

The 4,550-patient follow-up data, presented at the European Congress on Osteoporosis and Osteoarthritis in Valencia, Spain, showed treatment with Prolia (denosumab), a first-in-class, fully human monoclonal antibody designed to target RANK ligand, resulted in "robust BMD gains after five continuous years of treatment," i.e. 13.7% for lumbar spine BMD and 7.0% for total hip BMD.

In years four and five, women taking Prolia experienced further 1.9% and 1.7% increases in lumbar spine BMD and extra 0.7% and 0.6% increases in total hip BMD. Amgen also said the incidences of new osteoporotic fractures remained low for women taking Prolia for five years. Also, the women who transitioned from placebo to Prolia in the extension study showed significant BMD increases during the first two years of treatment: 7.9% in lumbar spine BMD and 4.1% in total hip BMD.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.